Why Dementia is Associated with Poor Morbidity and Novel Treatments: An In-Depth Discussion about Alzheimer’s Disease
DOI:
https://doi.org/10.54097/vnr8s295Keywords:
Alzheimer’s disease, β-amyloid peptide, neurofibrillary tangles, dementia, novel treatments.Abstract
One of the most common forms of dementia around the world is Alzheimer’s. By 2022, it is estimated one out of every three seniors diagnosed with Alzheimer’s will eventually die due to complications from the disease [1]. There are several biological and physical markers of Alzheimer’s that may indicate that one has the disease, with symptoms all relating to a decline in cognitive function. The general development of Alzheimer’s is ascribed to two factors, genetic and environmental. Along with the growth of an aging population and the absence of a definitive cure, the search for novel treatments has gained significant momentum. Some promising treatments include: immunotherapies targeting amyloid-beta plaques, such as the monoclonal antibody ‘donanemab’; precision medicine for personalized therapies, namely deep brain stimulation (DBS); and TRIM11 as a biological target for the slowing of the decline in cognitive abilities. Despite progression in the development of novel treatments, the pathophysiological mechanism of the disease is yet to be understood, accounting for various trial-and-error type experiments. Continued research and a comprehensive approach are vital for the development of effective therapies for Alzheimer’s disease.
Downloads
References
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., & Zalutsky, R. (2007). How common are the “common” neurologic disorders? In Neurology (Vol. 68, Issue 5, pp. 326–337). Ovid Technologies (Wolters Kluwer Health).
Silva, M. V. F., Loures, C. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019). Alzheimer's disease: risk factors and potentially protective measures. Journal of biomedical science, 26(1), 33.
2023 Alzheimer’s disease facts and figures. (2023). In Alzheimer’s & Dementia (Vol. 19, Issue 4, pp. 1598–1695). Wiley.
Breijyeh, Z., & Karaman, R. (2020). Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. In Molecules (Vol. 25, Issue 24, p. 5789). MDPI AG.
What Happens to the Brain in Alzheimer’s Disease? (2017, May 16). National Institute on Aging.
A. Armstrong, R. (2019). Risk factors for Alzheimer’s disease. In Folia Neuropathologica (Vol. 57, Issue 2, pp. 87–105). Termedia Sp. z.o.o.
Somatosensory Systems (Section 2, Chapter 2) Neuroscience Online: An Electronic Textbook for the Neurosciences | Department of Neurobiology and Anatomy - The University of Texas Medical School at Houston. (n.d.). Somatosensory Systems (Section 2, Chapter 2) Neuroscience Online: An Electronic Textbook for the Neurosciences | Department of Neurobiology and Anatomy - the University of Texas Medical School at Houston.
Le, H., & Lui, M. Y. (2023, March 27). Aphasia - StatPearls - NCBI Bookshelf. Aphasia - StatPearls - NCBI Bookshelf.
Ji, X., Wang, H., Zhu, M., He, Y., Zhang, H., Chen, X., Gao, W., & Fu, Y. (2020). Brainstem atrophy in the early stage of Alzheimer’s disease: a voxel-based morphometry study. In Brain Imaging and Behavior (Vol. 15, Issue 1, pp. 49–59). Springer Science and Business Media LLC.
Li, X.-L., Hu, N., Tan, M.-S., Yu, J.-T., & Tan, L. (2014). Behavioral and Psychological Symptoms in Alzheimer’s Disease. In BioMed Research International (Vol. 2014, pp. 1–9). Hindawi Limited.
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995). An english translation of alzheimer’s 1907 paper, Uber eine eigenartige erkankung der hirnrinde In Clinical Anatomy (Vol. 8, Issue 6, pp. 429–431). Wiley.
Knipe, H., & Gaillard, F. (2011). Alzheimer disease. In Radiopaedia.org. Radiopaedia.org.
Čolović, M. B., Krstić, D. Z., Lazarević-Pašti, T. D., Bondžić, A. M., & Vasić, V. M. (2013, May 1). Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. PubMed Central (PMC).
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019, March 20). Memantine for dementia. PubMed Central (PMC).
Cummings, J. L., Tong, G., & Ballard, C. (2019). Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. In Journal of Alzheimer’s Disease (Vol. 67, Issue 3, pp. 779–794). IOS Press.
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013, May 7). Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology.
Protein Identified as a Target for Alzheimer’s Treatment. (2023, July 27). Protein Identified as a Target for Alzheimer’s Treatment.
Zhang, Z.-Y., Harischandra, D. S., Wang, R., Ghaisas, S., Zhao, J. Y., McMonagle, T. P., Zhu, G., Lacuarta, K. D., Song, J., Trojanowski, J. Q., Xu, H., Lee, V. M.-Y., & Yang, X. (2023). TRIM11 protects against tauopathies and is down-regulated in Alzheimer’s disease. In Science (Vol. 381, Issue 6656). American Association for the Advancement of Science (AAAS).
Ktori, S. (2023, July 27). Tau-Protecting Protein Identified as Possible Gene Therapy for Alzheimer’s Disease. GEN - Genetic Engineering and Biotechnology News.
Rashad, A., Rasool, A., Shaheryar, M., Sarfraz, A., Sarfraz, Z., Robles-Velasco, K., & Cherrez-Ojeda, I. (2022). Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials. In Healthcare (Vol. 11, Issue 1, p. 32). MDPI AG.
Lowe, S. L., Willis, B. A., Hawdon, A., Natanegara, F., Chua, L., Foster, J., Shcherbinin, S., Ardayfio, P., & Sims, J. R. (2021, February 14). Donanemab (LY3002813) dose‐escalation study in Alzheimer’s disease. PubMed Central (PMC).
Gueorguieva, I., Willis, B. A., Chua, L., Chow, K., Ernest, C. S., II, Wang, J., Shcherbinin, S., Sims, J. R., & Chigutsa, E. (2023). Donanemab exposure and efficacy relationship using modeling in Alzheimer’s disease. In Alzheimer’s & Dementia: Translational Research & Clinical Interventions (Vol. 9, Issue 2). Wiley.
Brain-Stimulation Therapies for Alzheimer’s. (2022, August 10). WebMD.
Bittlinger, M., & Müller, S. (2018). Opening the debate on deep brain stimulation for Alzheimer disease – a critical evaluation of rationale, shortcomings, and ethical justification. In BMC Medical Ethics (Vol. 19, Issue 1). Springer Science and Business Media LLC.
Ríos, A. S., Oxenford, S., Neudorfer, C., Butenko, K., Li, N., Rajamani, N., Boutet, A., Elias, G. J. B., Germann, J., Loh, A., Deeb, W., Wang, F., Setsompop, K., Salvato, B., Almeida, L. B., Foote, K. D., Amaral, R., Rosenberg, P. B., Tang-Wai, D. F., Wolk, D. A., … Horn, A. (2022). Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer's disease. Nature communications, 13(1), 7707.
Deep Brain Stimulation for Alzheimer’s Not for Everyone. (2018, October 17). Johns Hopkins Medicine Newsroom.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
